Extensive Line of Anti-Human Protein Antibodies Available
By LabMedica International staff writers Posted on 23 Sep 2014 |
Image: A line of antibodies to human blood proteins offers high quality and flexibility in testing for a wide range of blood proteins (Photo courtesy of The Binding Site).
A line of antibodies to human blood proteins offers the in vitro diagnostics and life sciences sectors high quality and flexibility in testing for a wide range of blood proteins.
The Binding Site, Inc. (San Diego, CA, USA), a leader in manufacturing of primary antibodies and in discovery, development, manufacture, marketing, and sales of novel immunodiagnostic assays, now offers a comprehensive line of anti-human blood protein antibodies for the improvement of patient care. The availability of this extensive line will benefit the needs and efforts of clinical and life science researchers, medical laboratory professionals, and in vitro diagnostic (IVD) manufacturers alike. By utilization of innovative and patented manufacturing techniques, which yield highly specific antibodies, all in the Anti-Human Protein Antibodies line display the highest degrees of purity, shelf life stability, and lot-to-lot consistency.
The scope of antibodies available includes those against human acute-phase reactants, coagulation proteins, complement, immunoglobulins, and other blood proteins (i.e., albumin, prealbumin, transferrin, etc.).
All antibodies are available in an unconjugated format which may be conjugated to Biotin, Fluorescein-Isothiocyanate (FITC), Horseradish Peroxidase (HRP), Rhodamine, and others. Plus, a number of these antibodies are available from Binding Site already pre-conjugated to HRP, FITC, or both. These Anti-Human Protein Antibodies are offered in a convenient, operator-oriented standard packaging size of 1.0 mL, with customer distinct and bulk packaging configurations also being available.
Related Links:
The Binding Site
The Binding Site, Inc. (San Diego, CA, USA), a leader in manufacturing of primary antibodies and in discovery, development, manufacture, marketing, and sales of novel immunodiagnostic assays, now offers a comprehensive line of anti-human blood protein antibodies for the improvement of patient care. The availability of this extensive line will benefit the needs and efforts of clinical and life science researchers, medical laboratory professionals, and in vitro diagnostic (IVD) manufacturers alike. By utilization of innovative and patented manufacturing techniques, which yield highly specific antibodies, all in the Anti-Human Protein Antibodies line display the highest degrees of purity, shelf life stability, and lot-to-lot consistency.
The scope of antibodies available includes those against human acute-phase reactants, coagulation proteins, complement, immunoglobulins, and other blood proteins (i.e., albumin, prealbumin, transferrin, etc.).
All antibodies are available in an unconjugated format which may be conjugated to Biotin, Fluorescein-Isothiocyanate (FITC), Horseradish Peroxidase (HRP), Rhodamine, and others. Plus, a number of these antibodies are available from Binding Site already pre-conjugated to HRP, FITC, or both. These Anti-Human Protein Antibodies are offered in a convenient, operator-oriented standard packaging size of 1.0 mL, with customer distinct and bulk packaging configurations also being available.
Related Links:
The Binding Site
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form